Therapeutic strategies for the treatment of spinal muscular atrophy

Jonathan J. Cherry, Elliot J. Androphy

Research output: Contribution to journalReview article

16 Scopus citations

Abstract

Spinal muscular atrophy (SMA) is an inherited neurodegenerative disease that results in progressive dysfunction of motor neurons of the anterior horn of the spinal cord. SMA is caused by the loss of full-length protein expression from the survival of motor neuron 1 (SMN1) gene. The disease has a unique genetic profile as it is autosomal recessive for the loss of SMN1, but a nearly identical homolog, SMN2, acts as a disease modifier whose expression is inversely correlated to clinical severity. Targeted therapeutic approaches primarily focus on increasing the levels of full-length SMN protein, through either gene replacement or regulation of SMN2 expression. There is currently no US FDA approved treatment for SMA. This is an exciting time as multiple efforts from academic and industrial laboratories are reaching the preclinical and clinical testing stages.

Original languageEnglish (US)
Pages (from-to)1733-1750
Number of pages18
JournalFuture Medicinal Chemistry
Volume4
Issue number13
DOIs
StatePublished - Sep 1 2012

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Therapeutic strategies for the treatment of spinal muscular atrophy'. Together they form a unique fingerprint.

  • Cite this